TCL Archive NCI Advisors To Evaluate SPORE Program; Large Grants to Be Weighed Against R01s December 12, 1997
TCL Archive Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says September 6, 2002
TCL Archive Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now December 2, 1983
